Molecular Partners Presents Clinical Data Supporting Its Ongoing MP0533 Study And Preclinical Data On Next-Gen Conditioning Agent MP0621 At ASH 2024
Molecular Partners Presents Clinical Data Supporting Its Ongoing MP0533 Study And Preclinical Data On Next-Gen Conditioning Agent MP0621 At ASH 2024 . (MENAFN - EIN Presswire) 
 
  MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108968689/Molecular-Partners-Presents-Clinical-Data-Supporting-Its-Ongoing-MP0533-Study-And-Preclinical-Data-On-Next-Gen-Conditioning-Agent-MP0621-At-ASH-2024
2024-12-08
rss
(MENAFN - EIN Presswire) 
 
  MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical ...
Molecular Partners Presents Clinical Data Supporting Its Ongoing MP0533 Study And Preclinical Data On Next-Gen Conditioning Agent MP0621 At ASH 2024